Cohance Lifesciences Executive and Leadership Team

Yann D'Herve, the Chief Executive Officer at Cohance Lifesciences, directs the overarching corporate strategy for the global CDMO operations. D'Herve manages the expansion of Antibody Drug Conjugates and Nucleic Acid Chemistry services to meet the evolving demands of pharmaceutical innovators. By aligning internal resources with market requirements, the Chief Executive Officer ensures the organization maintains a competitive edge in complex molecule development. Yann D'Herve oversees the integration of discovery and commercial-scale manufacturing capabilities to support client pipelines across international markets. This leadership role involves constant collaboration with the Board to refine long-term growth objectives and operational efficiency. Through rigorous oversight of quality standards and sustainable practices, the Chief Executive Officer drives the company toward its goal of becoming a premier partner for global pharmaceutical firms. D'Herve secures the necessary infrastructure to support high-growth initiatives while maintaining the highest levels of technical precision.

Gunjan Singh, the Chief Executive Officer, Api Plus (Api & Formulations) at Cohance Lifesciences, manages the specialized division dedicated to small molecule API development and advanced formulations. Singh directs the technical teams responsible for scaling complex chemical processes from clinical phases to full commercial production. By optimizing manufacturing workflows, the Chief Executive Officer, Api Plus (Api & Formulations) ensures consistent output quality for global pharmaceutical partners. Gunjan Singh coordinates with cross-functional departments to streamline the transition of molecules through the development lifecycle. This leadership role focuses on enhancing the efficiency of API synthesis and formulation techniques to reduce time-to-market for clients. Through strategic resource allocation, Singh supports the expansion of the company's manufacturing footprint. The Chief Executive Officer, Api Plus (Api & Formulations) maintains a rigorous focus on regulatory compliance and operational excellence, ensuring that all production activities align with the broader mission of delivering high-quality pharmaceutical solutions.

Umang Vohra, the Executive Chairman & Global Chief Executive Officer at Cohance Lifesciences, architects the high-level vision and global market positioning for the entire organization. Vohra directs the strategic alignment of all business units, ensuring that the CDMO services remain at the forefront of pharmaceutical innovation. Umang Vohra oversees the company's international expansion efforts, driving growth across diverse geographic regions to capture emerging opportunities in the life sciences sector. This leadership role involves deep engagement with stakeholders to foster long-term value creation and operational stability. By championing a culture of quality and innovation, the Executive Chairman & Global Chief Executive Officer ensures that the company remains a trusted partner for complex molecule development. Vohra manages the integration of new technologies and service offerings to address the sophisticated needs of global pharmaceutical innovators. Through decisive leadership, the Executive Chairman & Global Chief Executive Officer secures the company's status as a leader in the global CDMO landscape.

Sunil Uttarwar, the Chief Operating Officer, Technology Operations at Cohance Lifesciences, directs the implementation of advanced manufacturing technologies and technical infrastructure. Uttarwar oversees the deployment of specialized equipment and digital systems required for complex API and nucleic acid chemistry processes. By optimizing technical workflows, the Chief Operating Officer, Technology Operations ensures that all manufacturing facilities operate at peak efficiency and safety standards. Sunil Uttarwar collaborates with engineering and research teams to integrate cutting-edge methodologies into the production pipeline. This leadership role focuses on scaling technical capabilities to support the increasing complexity of client projects. Through the management of technology-driven initiatives, Uttarwar enhances the company's ability to deliver high-precision manufacturing services. The Chief Operating Officer, Technology Operations maintains a constant focus on process innovation, ensuring that the organization remains capable of meeting the rigorous demands of the global pharmaceutical industry while upholding strict quality and sustainability benchmarks.

Ravinath Shetty, the Chief Operating Officer, Platform at Cohance Lifesciences, manages the foundational operational platforms that support the company's diverse service offerings. Shetty directs the cross-functional systems and administrative frameworks that enable seamless project execution from discovery to commercial scale. By streamlining internal processes, the Chief Operating Officer, Platform ensures that all departments maintain high levels of productivity and operational synergy. Ravinath Shetty oversees the implementation of standardized protocols across the organization to guarantee consistency in service delivery. This leadership role involves managing the operational backbone of the company, including supply chain coordination and resource management. Through the optimization of platform-wide initiatives, Shetty supports the company's ability to scale operations in response to market demand. The Chief Operating Officer, Platform drives continuous improvement efforts, ensuring that the organizational structure remains agile and responsive to the complex needs of pharmaceutical innovators across all global markets.